Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy

Table 1 Clinical characteristics of treatment groups (mean ± SD) n (%)

	Pantoprazole group(n = 52)	Somatostatin group(n = 49)	Total cohort(n = 101)	P value
Sex (male)	19 (36.5)	13 (26.5)	32 (31.7)	0.280
Age (yr)	65.44 ± 19.46	64.24 ± 14.13	64.86 ± 17.01	0.735
Hemodynamic shock	26 (50.0)	27 (55.1)	53 (52.5)	0.608
Helicobacter pylori infection	14 (26.9)	8 (16.3)	22 (21.8)	0.197
Hemoglobin (g/dL)	8.56 ± 2.84	8.26 ± 2.61	8.41 ± 2.72	0.857
Hemoglobin < 7 g/dL	17 (32.7)	16 (32.7)	33 (32.7)	0.997
Blood urea nitrogen (mg/dL)	40.20 ± 27.06	39.47 ± 26.83	39.84 ± 26.82	0.920
Creatinine (mg/dL)	1.17 ± 0.80	1.29 ± 1.33	1.23 ± 1.09	0.187
Albumin (g/dL)	3.12 ± 0.54	2.79 ± 0.59	2.96 ± 0.59	0.173
Type 2 diabetes mellitus	12 (23.1)	16 (32.7)	28 (27.7)	0.283
Hypertension	22 (43.3)	19 (38.8)	41 (40.6)	0.718
Heart failure	7 (13.5)	4 (8.2)	11 (10.9)	0.393
Ischemic heart disease	15 (28.8)	11 (22.4)	26 (25.7)	0.462
Antiplatelet medication	24 (46.2)	20 (40.8)	44 (43.6)	0.589
NSAID	6 (11.5)	3 (6.1)	9 (8.9)	0.340
Multiple antiplatelet medications	5 (9.6)	2 (4.1)	7 (6.9)	0.274
Steroids	2 (3.8)	4 (8.2)	6 (5.9)	0.359
Melena	31 (59.6)	28 (57.1)	59 (58.4)	0.801
Hematemesis	28 (53.8)	32 (65.3)	60 (59.4)	0.241
Hematochezia	2 (3.8)	5 (10.2)	7 (6.9)	0.209
Complete Rockall score	6.84 ± 1.47	6.87 ± 1.31	6.86 ± 1.39	0.911
Rockall score > 6	26 (50.0)	29 (59.2)	55 (54.5)	0.354
Early rebleeding	6 (12.2)	7 (14.3)	13 (13.3)	0.766

NSAID: Non-steroidal anti-inflammatory drug.